04/02/2026
At CHR, we’re proud to launch our IRB-approved clinical trial on hCG ovarian priming, designed to improve IVF outcomes in women with diminished ovarian reserve (DOR).
Traditional IVF focuses on later-stage follicle growth. Our approach goes earlier: targeting preantral follicle development through low-dose high priming from four weeks before stimulation. By activating LH receptors at this critical stage, we aim to recruit more follicles and increase the number of mature eggs available for fertilization.
This is translational ART in action - evidence-based, innovative, and already integrated into patient care.
